Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA

[1]  U. Zettl,et al.  Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients , 2018, Expert opinion on pharmacotherapy.

[2]  H. Goossens,et al.  Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. , 2017, Blood.

[3]  Hua Li,et al.  Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice , 2017, Molecular medicine.

[4]  Z. Berneman,et al.  Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients , 2016, Journal of Neuroinflammation.

[5]  R. Hohlfeld,et al.  The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets , 2016, The Lancet Neurology.

[6]  D. Merkler,et al.  pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation , 2016, Journal of autoimmunity.

[7]  Jeoung-Sook Shin,et al.  The Role of Dendritic Cells in Central Tolerance , 2015, Immune network.

[8]  B. Hemmer,et al.  Role of the innate and adaptive immune responses in the course of multiple sclerosis , 2015, The Lancet Neurology.

[9]  Christophe Coillot,et al.  Correlation of in vivo and ex vivo 1H-MRI with histology in two severities of mouse spinal cord injury , 2015, Front. Neuroanat..

[10]  E. Martínez-Cáceres,et al.  Beneficial Effect of Tolerogenic Dendritic Cells Pulsed with MOG Autoantigen in Experimental Autoimmune Encephalomyelitis , 2015, CNS neuroscience & therapeutics.

[11]  D. Arnold,et al.  Epitope spreading as an early pathogenic event in pediatric multiple sclerosis , 2014, Neurology.

[12]  H. Goossens,et al.  Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors , 2014, Multiple sclerosis.

[13]  Y. Nakatsuji,et al.  Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model. , 2014, International immunology.

[14]  J. Greer.  Autoimmune T-Cell Reactivity to Myelin Proteolipids and Glycolipids in Multiple Sclerosis , 2013, Multiple sclerosis international.

[15]  H. Fan,et al.  A Mouse Model of Adoptive Immunotherapeutic Targeting of Autoimmune Arthritis Using Allo-Tolerogenic Dendritic Cells , 2013, PloS one.

[16]  M. Jaimes,et al.  A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) , 2013, Cytometry Part A.

[17]  Z. Berneman,et al.  Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies? , 2013, Multiple sclerosis.

[18]  Guang-Xian Zhang,et al.  Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10+ IFN-γ+-producing CD4+ T cells , 2013, Immunologic research.

[19]  C. Fraefel,et al.  Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis , 2012, Gene Therapy.

[20]  B. Neyns,et al.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  F. Borràs,et al.  Specific T‐cell proliferation to myelin peptides in relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.

[22]  John H. Robinson,et al.  Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. , 2010, Arthritis and rheumatism.

[23]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[24]  J. Isaacs,et al.  Development of Dendritic Cell-Based Immunotherapy for Autoimmunity , 2010, International reviews of immunology.

[25]  R. Hintzen,et al.  Surgical excision of CNS‐draining lymph nodes reduces relapse severity in chronic‐relapsing experimental autoimmune encephalomyelitis , 2009, The Journal of pathology.

[26]  C. Klein,et al.  Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency--lessons learned from monogenic disorders in mice and men. , 2008, Current opinion in immunology.

[27]  R. Huber,et al.  Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific Autoantibody Response Is Focused on One Dominant Conformational Epitope Region in Rodents12 , 2008, The Journal of Immunology.

[28]  S. Hillion,et al.  Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals , 2008, European journal of immunology.

[29]  A. Mackensen,et al.  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.

[30]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[31]  Geert Molenberghs,et al.  Missing Data in Clinical Studies , 2007 .

[32]  S. Anderton,et al.  Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35–55 region of myelin oligodendrocyte glycoprotein , 2007, Journal of Neuroimmunology.

[33]  James A. Bovaird,et al.  Statistical analysis of data from studies on experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[34]  P. Verginis,et al.  Tolerogenic Semimature Dendritic Cells Suppress Experimental Autoimmune Thyroiditis by Activation of Thyroglobulin-Specific CD4+CD25+ T Cells1 , 2005, The Journal of Immunology.

[35]  P. Pierre,et al.  Understanding the cell biology of antigen presentation: the dendritic cell contribution. , 2003, Current opinion in cell biology.

[36]  A. Enk,et al.  Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.

[37]  N. Viner,et al.  Influence of a dominant cryptic epitope on autoimmune T cell tolerance , 2002, Nature Immunology.

[38]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  X. Montalban,et al.  Specific Proliferation Towards Myelin Antigens in Patients with Multiple Sclerosis During a Relapse , 2002, Autoimmunity.

[40]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[41]  R. Hohlfeld,et al.  Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. , 2000, Brain : a journal of neurology.

[42]  A. Tomlinson,et al.  Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. , 1999, The Journal of clinical investigation.

[43]  R. Kinkel,et al.  The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis , 1998, Immunological reviews.

[44]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[45]  H. McFarland,et al.  Epitope spreading occurs in active but not passive EAE induced by myelin basic protein , 1996, Journal of Neuroimmunology.

[46]  V. Tuohy,et al.  A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease , 1996, The Journal of experimental medicine.

[47]  S. Miller,et al.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis , 1995, The Journal of experimental medicine.

[48]  A. Vincent,et al.  Approaches for Studying the Pathogenic T Cells in Autoimmune Patients a , 1993, Annals of the New York Academy of Sciences.

[49]  H. Lassmann,et al.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement , 1991, Journal of Neuroimmunology.

[50]  Eric O Long,et al.  Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. , 1990, Journal of immunology.

[51]  Z. Berneman,et al.  GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use. , 2016, Methods in molecular biology.

[52]  D. V. van Bockstaele,et al.  Messenger Rna Electroporation: an Efficient Tool in Immunotherapy and Stem Cell Research , 2022 .

[53]  R. Kinkel,et al.  Epitope spreading: a mechanism for progression of autoimmune disease. , 2000, Archivum immunologiae et therapiae experimentalis.

[54]  C. Rorden,et al.  Stereotaxic display of brain lesions. , 2000, Behavioural neurology.

[55]  Tuohy Vk,et al.  Epitope spreading: a mechanism for progression of autoimmune disease. , 2000 .